Fintel reports that on May 16, 2025, UBS downgraded their outlook for Iovance Biotherapeutics (LSE:0JDK) from Buy to Neutral.
Analyst Price Forecast Suggests 1,142.32% Upside
As of May 7, 2025, the average one-year price target for Iovance Biotherapeutics is 20.74 GBX/share. The forecasts range from a low of 5.35 GBX to a high of 35.62 GBX. The average price target represents an increase of 1,142.32% from its latest reported closing price of 1.67 GBX / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Iovance Biotherapeutics is 454MM, an increase of 113.41%. The projected annual non-GAAP EPS is -0.82.
What is the Fund Sentiment?
There are 524 funds or institutions reporting positions in Iovance Biotherapeutics. This is an decrease of 4 owner(s) or 0.76% in the last quarter. Average portfolio weight of all funds dedicated to 0JDK is 0.11%, an increase of 38.88%. Total shares owned by institutions increased in the last three months by 0.15% to 274,044K shares.
What are Other Shareholders Doing?
Mhr Fund Management holds 24,417K shares representing 7.31% ownership of the company. No change in the last quarter.
Perceptive Advisors holds 12,712K shares representing 3.81% ownership of the company. In its prior filing, the firm reported owning 22,112K shares , representing a decrease of 73.95%. The firm decreased its portfolio allocation in 0JDK by 66.93% over the last quarter.
Long Focus Capital Management holds 9,250K shares representing 2.77% ownership of the company. In its prior filing, the firm reported owning 5,132K shares , representing an increase of 44.52%. The firm decreased its portfolio allocation in 0JDK by 16.57% over the last quarter.
Hood River Capital Management holds 9,216K shares representing 2.76% ownership of the company. In its prior filing, the firm reported owning 8,992K shares , representing an increase of 2.44%. The firm decreased its portfolio allocation in 0JDK by 46.70% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 8,609K shares representing 2.58% ownership of the company. In its prior filing, the firm reported owning 8,718K shares , representing a decrease of 1.27%. The firm decreased its portfolio allocation in 0JDK by 23.31% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
